California Public Employees Retirement System Kodiak Sciences Inc. Transaction History

California Public Employees Retirement System

$147 Billion
Q4 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 04, 2022	SELL	$7.09 - $89.45 $533,338 - $6.73 Million	-75,224 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$81.97 - $106.94 $117,217 - $152,924	1,430 Added 1.94%	75,224 $7.22 Million
Q2 2021 Aug 13, 2021	SELL	$77.2 - $126.54 $245,650 - $402,650	-3,182 Reduced 4.13%	73,794 $6.86 Million
Q1 2021 May 14, 2021	BUY	$110.45 - $164.47 $281,426 - $419,069	2,548 Added 3.42%	76,976 $8.73 Million
Q4 2020 Feb 02, 2021	BUY	$60.78 - $154.03 $505,811 - $1.28 Million	8,322 Added 12.59%	74,428 $10.9 Million
Q3 2020 Nov 05, 2020	BUY	$45.05 - $59.27 $67,575 - $88,905	1,500 Added 2.32%	66,106 $3.91 Million
Q2 2020 Aug 12, 2020	BUY	$42.74 - $66.25 $443,598 - $687,608	10,379 Added 19.14%	64,606 $3.5 Million
Q1 2020 May 12, 2020	BUY	$38.18 - $73.95 $328,348 - $635,970	8,600 Added 18.85%	54,227 $2.59 Million
Q4 2019 Jan 27, 2020	BUY	$13.9 - $76.65 $476,325 - $2.63 Million	34,268 Added 301.68%	45,627 $3.28 Million
Q3 2019 Oct 31, 2019	BUY	$10.24 - $17.57 $116,316 - $199,577	11,359 New	11,359 $163,000

Others Institutions Holding KOD

# of Institutions

109

Shares Held

40.9M

Call Options Held

28.4K

Put Options Held

21.2K

Baker Bros. Advisors LP New York, NY

17.3M
Shares

$77 Million
1.91% of portfolio
Black Rock Inc. New York, NY

3.85M
Shares

$17.1 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

1.68M
Shares

$7.49 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

1.53M
Shares

$6.82 Million
0.04% of portfolio
Price T Rowe Associates Inc Baltimore, MD

1.27M
Shares

$5.64 Million
0.0% of portfolio

View Full List

About Kodiak Sciences Inc.

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $232M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

More about KOD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.

Account